Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

ClinicalTrials.gov ID: NCT02013531

Public ClinicalTrials.gov record NCT02013531. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Study identification

NCT ID
NCT02013531
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Enrollment
37 participants

Conditions and interventions

Interventions

  • Brexpiprazole Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2013
Primary completion
Apr 30, 2014
Completion
May 31, 2014
Last update posted
Mar 28, 2016

2013 – 2014

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Not listed Tuscon Arizona 85712
Not listed Garden Grove California 92845
Not listed Oceanside California 92056
Not listed Temecula California 92591
Not listed Gainesville Florida 32607
Not listed Jacksonville Florida 32256
Not listed Miami Florida 33145
Not listed Atlanta Georgia 30308
Not listed Lafayette Indiana 47905
Not listed Baltimore Maryland 21208
Not listed Boston Massachusetts 02131
Not listed Haverhill Massachusetts 01830
Not listed Rochester Hills Michigan 48307
Not listed New York New York 10168
Not listed Staten Island New York 10305
Not listed Salem Oregon 97301
Not listed Allentown Pennsylvania 18104
Not listed Arlington Texas 76012
Not listed Austin Texas 78731
Not listed Woodstock Vermont 05091
Not listed Richmond Virginia 23230

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02013531, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 28, 2016 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02013531 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →